Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial

Circ Arrhythm Electrophysiol. 2021 Mar;14(3):e009614. doi: 10.1161/CIRCEP.120.009614. Epub 2021 Mar 4.

Authors

Sana M Al-Khatib¹, Hillary Mulder¹, Daniel Wojdyla¹, Renato D Lopes¹, Lars Wallentin², John H Alexander¹, Ziad Hijazi², Shinya Goto³, Christopher B Granger¹

Affiliations

¹ Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.M.A.-K., H.M., D.W., R.D.L., J.H.A., C.B.G.).
² Uppsala Clinical Research Center, Uppsala University, Sweden (L.W., Z.H.).
³ Tokai University School of Medicine, Isehara, Japan (S.G.).

PMID: 33657831
DOI: 10.1161/CIRCEP.120.009614

No abstract available

Keywords: anticoagulants; apixaban; atrial fibrillation; hypertrophy; warfarin.

Publication types

Clinical Trial
Comparative Study
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anticoagulants / adverse effects
Anticoagulants / therapeutic use*
Atrial Fibrillation / complications
Atrial Fibrillation / diagnosis
Atrial Fibrillation / drug therapy*
Atrial Fibrillation / physiopathology
Factor Xa Inhibitors / adverse effects
Factor Xa Inhibitors / therapeutic use*
Humans
Hypertrophy, Left Ventricular / complications*
Hypertrophy, Left Ventricular / diagnostic imaging
Hypertrophy, Left Ventricular / physiopathology
Prospective Studies
Pyrazoles / adverse effects
Pyrazoles / therapeutic use*
Pyridones / adverse effects
Pyridones / therapeutic use*
Risk Assessment
Risk Factors
Stroke / diagnosis
Stroke / etiology
Stroke / prevention & control*
Thromboembolism / diagnosis
Thromboembolism / etiology
Thromboembolism / prevention & control*
Time Factors
Treatment Outcome
Ventricular Function, Left
Ventricular Remodeling
Warfarin / adverse effects
Warfarin / therapeutic use*

Substances

Anticoagulants
Factor Xa Inhibitors
Pyrazoles
Pyridones
apixaban
Warfarin